TrialHuman vaccines & immunotherapeutics2026

A first-in-human Phase 1/1b randomized trial evaluating the safety and immunogenicity of a respiratory syncytial virus (RSV) virus-like particle subunit vaccine (IVX-121) in healthy young and older adults.

Ilse De Coster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.